Nanoplatform‐Enabled Genetic Interventions for Central Nervous System Disorders: Advances in Delivery Strategies and Therapeutic Potential
Advanced Genetics · 2025-06 · 6 (2)
DOI: 10.1002/ggn2.202500010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Genetics, online erschienen am 24.06.2025. Verfasst von Fuming Liang und 4 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Standardization and Measurement for Nanotechnology National Center for Nanoscience and Technology Beijing 100190 P. R. China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Central nervous system (CNS) disorders are driven by complex genetic and epigenetic factors. While gene‐based interventions (siRNA, mRNA, CRISPR systems, etc.) hold transformative potential, their clinical application is severely constrained by inefficient delivery, especially across the blood‐brain barrier. Nanocarriers have emerged as transformative platforms that overcome these challenges by enabling efficient BBB penetration while ensuring precise biodistribution control and enhanced therapeutic payload protection. This review explores recent advances in nanoplatform‐enabled genetic intervention that overcome the delivery challenges through innovative engineering approaches. We discuss the genetic and epigenetic mechanisms underlying major CNS pathologies, the current limitations of free nucleic acid therapeutics, the development of advanced nanoplatforms that achieve blood‐brain barrier penetration and targeted delivery. We further also evaluate therapeutic prospects across disease models while addressing translational challenges in stability, targeting specificity, and manufacturing scalability. By integrating fundamental research with preclinical applications, this review provides both a theoretical framework and practical roadmap for developing next‐generation nanotherapeutics for CNS genetic medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CAS Key Laboratory of Standardization and Measurement for Nanotechnology National Center for Nanoscience and Technology Beijing 100190 P. R. China.
- Department of Neurosurgery The First Affiliated Hospital of Chongqing Medical University 1 Friendship Road Chongqing 400016 P. R. China.
- Chengdu Medical College Chengdu 610500 P. R. China.
- Institute of Blood Transfusion Chinese Academy of Medical Sciences Peking Union Medical College Chengdu 610052 P.R. China.
- University of Chinese Academy of Sciences Beijing 100049 P. R. China.
ORCID-Profile: Ling Zhu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Liang, F., Cui, S., Yang, J., He, Z., & Zhu, L. (2025). Nanoplatform‐Enabled Genetic Interventions for Central Nervous System Disorders: Advances in Delivery Strategies and Therapeutic Potential. Advanced Genetics, 6(2). https://doi.org/10.1002/ggn2.202500010
Vancouver
Liang F, Cui S, Yang J, He Z, Zhu L. Nanoplatform‐Enabled Genetic Interventions for Central Nervous System Disorders: Advances in Delivery Strategies and Therapeutic Potential. Advanced Genetics. 2025;6(2). doi:10.1002/ggn2.202500010
BibTeX
@article{Liang2025,
author = {Liang, Fuming and Cui, Shizhen and Yang, Jing and He, Zhaohui and Zhu, Ling},
title = {Nanoplatform‐Enabled Genetic Interventions for Central Nervous System Disorders: Advances in Delivery Strategies and Therapeutic Potential},
journal = {Advanced Genetics},
year = {2025},
volume = {6},
number = {2},
doi = {10.1002/ggn2.202500010}
}
EUVIMED